Skip to content
AnalystLens

CVS · CVS HEALTH Corp

50 filings

10-Q

CVS 10-Q Quarterly Reports

CVS HEALTH Corp - 50 quarterly reports

Filing record · 2016–202610-K1110-Q328-K181

CVS filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 181 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Leadership change8-K · Aug ’19Aug ’19
  3. Impairment8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Apr ’25Apr ’25
  1. 2026-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2026

    CVS Health Corporation reported strong financial performance for the second quarter and first half of 2026, with total revenues increasing by 7.3% and 6.7% year-over-year, respectively. This growth was driven by robust performance across all operating segments, particularly in 'Products' and 'Services.' The company saw a significant improvement in operating income, which more than doubled year-over-year for the quarter and increased by 63.0% for the first half, largely due to the absence of significant legacy litigation charges recorded in the prior year and improved operating performance across segments. Net income attributable to CVS Health also showed substantial growth, up 191.8% for the quarter and 111.5% for the first half, reflecting the strong operational improvements and a lower effective tax rate. The company maintained a healthy liquidity position with over $11.3 billion in cash and cash equivalents, and operating cash flow significantly improved year-over-year. Despite ongoing litigation and regulatory matters, the company's core business segments demonstrated resilience and growth.

    Aug 5, 2026
  2. 2026-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2026

    CVS Health Corporation reported a strong first quarter for 2026, demonstrating significant revenue and net income growth compared to the prior year. Total revenues increased by 6.2% to $100.4 billion, driven by robust performance across all operating segments, particularly in Health Services and Pharmacy & Consumer Wellness, with notable contributions from pharmacy drug mix and brand inflation. Net income saw a substantial increase of 65.9% to $2.96 billion. This growth was significantly aided by the absence of large one-time charges incurred in the prior year, such as the legacy litigation charge and the loss on Accountable Care assets. The effective income tax rate also improved due to these factors. The company maintained a solid liquidity position with $9.5 billion in cash and cash equivalents, and continues to return value to shareholders through consistent dividend payments.

    May 6, 2026
  3. 2025-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2025

    CVS Health's Q3 2025 10-Q shows a sharply weaker quarter on a GAAP basis, driven by a $5.7 billion non-cash goodwill impairment on its Health Care Delivery reporting unit (Signify Health and Oak Street Health). Revenue still grew 7.8% year over year to $102.9 billion, and the Health Care Benefits segment swung from an adjusted operating loss of $924 million to adjusted operating income of $314 million, helped by an improved medical benefit ratio of 92.8% versus 95.2%. Consolidated GAAP operating results were a loss of $3.2 billion, and the company posted a net loss attributable to CVS Health of $3.98 billion, or $(3.13) per share, versus net income of $87 million a year earlier. The nine-month picture is also weaker, with a net loss of $1.2 billion, driven by the impairment, $1.2 billion of legacy litigation charges, a $320 million opioid charge, and losses tied to the wind-down of Accountable Care assets. The quarter also included a $483 million gain from deconsolidating Omnicare after its September 2025 Chapter 11 filing. Operating cash flow was roughly flat at $7.2 billion for the nine months, and the company kept its $0.665 quarterly dividend. Management flagged continued elevated utilization, Medicaid cost pressure, and the planned exit from individual exchange markets in January 2026. The impairment note also says the remaining Health Care Delivery goodwill of about $4.2 billion has no headroom, so further impairment is reasonably possible if forecasts are missed. Debt ratings remain investment grade (BBB/Baa3/BBB), though the S&P and Fitch outlooks are negative. For investors, the central questions are whether the Health Care Benefits margin recovery is durable through the 2026 Medicare Advantage bid cycle, whether Health Care Delivery can deliver its revised projections, and how much pending litigation (including the appeals of the $291 million PBM judgment and the Omnicare False Claims Act penalties) could ultimately cost. The company has about $9.1 billion of cash and $64.6 billion of long-term debt principal, so liquidity is not the immediate concern, but the earnings volatility and the negative outlook warrant close monitoring.

    Oct 29, 2025
  4. 2025-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2025

    CVS Health Corporation reported a significant increase in total revenues for the three and six months ended June 30, 2025, up 8.4% and 7.7% respectively, driven by growth across all segments, particularly in Premiums and Products. However, the quarter was impacted by substantial litigation charges, leading to a decrease in net income for the three-month period by 42.7% and a slight decline of 3.4% for the six-month period compared to the prior year. Despite revenue growth, increased operating expenses, largely attributable to these litigation charges and a loss on Accountable Care assets, also pressured operating income. Looking ahead, CVS Health faces ongoing challenges including declining medical membership in Medicare and individual exchange products, potential utilization pressures impacting its Health Care Benefits segment, and ongoing regulatory scrutiny on its PBM practices. The company plans to exit individual public health insurance exchanges in 2026. Despite these headwinds, the company is focused on cost savings initiatives and expects benefits from market disruptions in the retail pharmacy sector.

    Jul 31, 2025
  5. 2025-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2025

    CVS Health Corporation reported solid top-line growth in the first quarter of 2025, with total revenues increasing by 7.0% year-over-year to $94.6 billion. This growth was broad-based across its segments, driven by higher product and premium revenues. The company demonstrated significant improvement in operating income, which surged by 48.6% to $3.4 billion, largely due to favorable prior-year development and improved performance in its Health Care Benefits segment, partially offset by one-time charges including a $387 million litigation charge related to the Omnicare verdict and a $247 million loss on Accountable Care assets. Net income attributable to CVS Health also saw a substantial increase of 59.8% to $1.8 billion, resulting in diluted earnings per share of $1.41, a significant improvement from $0.88 in the prior year. Despite the strong profitability, the company noted a decline in its Medicare and individual exchange medical membership. Management highlighted continued pressure from utilization in its Health Care Benefits segment and a cautious outlook regarding potential future premium deficiency reserves. The company also reported strong cash flow from operations and a healthy cash position, while managing its debt levels and continuing its share repurchase program.

    May 1, 2025
  6. 2024-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2024

    CVS Health Corporation reported a significant decline in net income attributable to CVS Health for the third quarter and first nine months of 2024 compared to the same periods in 2023. This was largely driven by substantial restructuring charges of $1.2 billion in Q3 2024, a substantial increase in health care costs, and the recording of significant premium deficiency reserves, particularly within the Health Care Benefits segment. Total revenues saw a modest increase year-over-year, primarily due to growth in premiums and services, but this was outpaced by rising operating costs and health care expenses. Despite the reported net income decline, the company highlighted positive revenue growth in its Health Care Benefits and Pharmacy & Consumer Wellness segments. However, elevated utilization, especially in Medicare Advantage programs, along with medical cost pressures in the Medicaid business, continue to strain the Health Care Benefits segment, leading to substantial premium deficiency reserves. The company is also navigating ongoing litigation, including significant opioid settlements. Management has initiated an enterprise-wide restructuring plan to improve efficiency and reduce costs, which contributed to the substantial charges in the current quarter.

    Nov 6, 2024
  7. 2024-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2024

    CVS Health Corporation reported revenues of $91.23 billion for the second quarter of 2024, a 2.6% increase year-over-year, primarily driven by growth in its Health Care Benefits and Pharmacy & Consumer Wellness segments. However, net income attributable to CVS Health decreased by 6.9% to $1.77 billion, or $1.41 per diluted share. This decline was largely influenced by increased health care costs, particularly within the Health Care Benefits segment, where the Medical Benefit Ratio (MBR) rose to 89.6% due to higher utilization and the impact of reduced Medicare Advantage star ratings. The Health Services segment experienced an 8.8% revenue decrease due to client losses and pricing pressures, though adjusted operating income saw a slight increase. The company continued its strategic investments, including the integration of Oak Street Health and Signify Health, and actively managed its capital through share repurchases and debt issuance. Looking ahead, CVS Health anticipates continued elevated utilization in Medicare Advantage programs, which is expected to pressure its Health Care Benefits segment and health care delivery assets. The company also faces medical cost pressures in its Medicaid business due to higher acuity following member redeterminations. Despite these challenges, CVS Health expects growth in its newer ventures like Cordavis, Oak Street Health, and Signify Health, and is focused on enterprise-wide cost savings initiatives to improve its operating cost structure. The company maintains a strong liquidity position with $12.5 billion in cash and cash equivalents as of June 30, 2024.

    Aug 7, 2024
  8. 2024-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2024

    CVS Health Corporation reported total revenues of $88.4 billion for the first quarter of 2024, a 3.7% increase compared to the prior year, primarily driven by growth in its Health Care Benefits and Pharmacy & Consumer Wellness segments. However, net income attributable to CVS Health significantly decreased by 47.9% to $1.113 billion ($0.88 diluted EPS) from $2.136 billion ($1.65 diluted EPS) in the first quarter of 2023. This decline was largely attributed to increased Medicare utilization, unfavorable impacts from lower Medicare Advantage star ratings, and higher health care costs in the Health Care Benefits segment, as well as challenges in the Health Services segment including client price improvements and the loss of a large client. The company's operational performance reflects a mixed picture, with revenue growth being overshadowed by a substantial drop in profitability. While the Health Care Benefits segment saw strong revenue growth from Medicare and Commercial product lines, its Medical Benefit Ratio (MBR) increased significantly due to higher utilization. The Health Services segment experienced a revenue decline primarily due to client losses and pricing pressures, despite contributions from recent acquisitions. The Pharmacy & Consumer Wellness segment demonstrated solid revenue growth driven by increased prescription volume and favorable drug mix, alongside a slight increase in adjusted operating income. CVS Health's balance sheet remains robust with total assets of $249.7 billion. The company also continued its share repurchase program, repurchasing $3.0 billion of common stock in the quarter. Despite the profitability dip, the company's outlook suggests expected growth from new ventures like Cordavis, Oak Street Health, and Signify Health, though it anticipates continued pressure on its Health Care Benefits segment due to sustained high Medicare utilization.

    May 1, 2024
  9. 2023-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2023

    CVS Health Corporation reported a strong third quarter and year-to-date performance, with total revenues increasing by 10.6% to $89.8 billion for the quarter and 10.6% to $264.0 billion year-to-date. This growth was driven by increases across all segments, notably in Premiums (17.4% QoQ) and Services (52.8% QoQ) within the Health Care Benefits and Health Services segments, respectively. The company returned to operating income of $3.7 billion for the quarter, a significant turnaround from a $3.9 billion loss in the prior year, largely due to the absence of substantial opioid litigation and asset impairment charges. Key strategic moves, including the acquisitions of Oak Street Health and Signify Health, are integrating into the Health Services segment, contributing to revenue growth but also increasing operating expenses and interest expense due to higher debt levels. The company also announced the launch of Cordavis, a subsidiary focused on biosimilar products. Despite positive revenue trends, investors should monitor the Health Care Benefits segment's increased Medical Benefit Ratio (MBR) and the ongoing integration costs and debt servicing from recent acquisitions.

    Nov 1, 2023
  10. 2023-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2023

    CVS Health Corporation reported total revenues of $88.9 billion for the three months ended June 30, 2023, an increase of 10.3% compared to the prior year, driven by growth across all segments. Net income attributable to CVS Health was $1.9 billion, a decrease of 37.2% from the prior year, primarily impacted by increased operating expenses, restructuring charges, and acquisition-related costs. The company completed significant acquisitions of Oak Street Health and Signify Health during the period, which contributed to revenue growth but also increased operating expenses and debt. Despite a challenging quarter in terms of net income, the company generated strong operating cash flow and maintained a solid liquidity position. Key strategic initiatives include expanding value-based care through acquisitions and streamlining operations. While revenue growth remains robust, investors should monitor the impact of integration costs, increased interest expenses, and ongoing legal and regulatory matters, particularly those related to opioids and PBM practices, which could affect future profitability.

    Aug 2, 2023
  11. 2023-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2023

    CVS Health Corporation reported strong revenue growth of 11.0% year-over-year for the first quarter of 2023, reaching $85.3 billion. This increase was primarily driven by growth in its Products and Premiums segments. However, net income saw a decrease of 9.3% to $2.14 billion, or $1.65 per diluted share, compared to the prior year period. The company completed the acquisition of Signify Health for $7.4 billion in late March, significantly increasing its goodwill and intangible assets, and also announced the acquisition of Oak Street Health for $10.6 billion in early May. Operationally, the company recorded a $349 million loss on assets held for sale related to its Omnicare long-term care business. The company also noted a significant increase in net cash provided by operating activities, largely due to the early receipt of CMS payments. Despite the dip in net income, the company's strategic acquisitions and continued revenue growth across its segments signal a focus on expanding its health services capabilities and value-based care offerings.

    May 3, 2023
  12. 2022-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2022

    CVS Health Corporation's third-quarter 2022 report shows a significant increase in total revenues, up 10.0% year-over-year to $81.2 billion, driven by strong performance across all segments, particularly in 'Products' and 'Premiums'. However, the company reported a substantial operating loss of $3.9 billion for the quarter, a significant shift from the prior year's operating income. This loss was primarily attributable to a $5.2 billion charge related to opioid litigation settlements and a $2.5 billion loss on assets held for sale for its long-term care business. Despite these charges, the company's adjusted operating income, which excludes these one-time items and other adjustments, increased to $4.2 billion, reflecting underlying operational strength in its Health Care Benefits and Pharmacy Services segments. For the first nine months of 2022, total revenues also grew by 10.7% to $238.6 billion. The company generated net income attributable to CVS Health of $1.8 billion, a notable decrease from $6.6 billion in the same period last year, largely due to the aforementioned opioid litigation charges and the loss on assets held for sale. The company's cash flow from operations saw a significant increase of $3.9 billion year-over-year, ending the quarter with a healthy cash balance of $17.2 billion. Investors should note the ongoing integration of the proposed Signify Health acquisition, expected to close in the first half of 2023, which is subject to regulatory approval.

    Nov 2, 2022
  13. 2022-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2022

    CVS Health Corporation reported solid financial results for the second quarter and first half of 2022, with total revenues increasing by 11.0% year-over-year for the quarter to $80.6 billion and 11.1% for the first half to $157.5 billion. This growth was driven by strong performance across all segments, particularly in Products and Premiums. Net income attributable to CVS Health increased by 6.0% for the quarter to $2.95 billion and 5.1% for the first half to $5.26 billion. The company also benefited from the divestiture of PayFlex, which contributed a pre-tax gain of $225 million in the second quarter. Despite facing ongoing operational costs and legal settlements, including a significant opioid settlement with the State of Florida, CVS Health demonstrated resilience and continued to return capital to shareholders through share repurchases and dividends. The company's outlook remains focused on integrating its health services offerings and driving cost efficiencies.

    Aug 3, 2022
  14. 2022-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2022

    CVS Health Corporation reported solid revenue growth for the first quarter of 2022, with total revenues increasing by 11.2% year-over-year to $76.8 billion. This growth was primarily driven by strong performance across all segments, including Pharmacy Services and Retail/LTC, bolstered by increased prescription volume, specialty pharmacy growth, and front-store sales. While overall revenue saw a healthy increase, operating income experienced a slight decline of 2.4% to $3.5 billion. This decrease was largely attributable to a significant legal settlement accrual of $484 million related to opioid claims with the State of Florida. Despite this, the company demonstrated effective cost management, with operating expenses as a percentage of revenue remaining stable. The company also returned capital to shareholders through share repurchases and dividends, reflecting confidence in its ongoing operational strength.

    May 4, 2022
  15. 2021-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2021

    CVS Health Corporation reported solid revenue growth for the nine months ended September 30, 2021, with total revenues increasing by 8.2% to $215.5 billion, driven by strong performance across all segments. Net income attributable to CVS Health saw a comparable increase of 6.4% to $6.6 billion. The company experienced a notable goodwill impairment of $431 million in the Retail/LTC segment, impacting operating income. Despite the goodwill impairment, the company demonstrated resilience with increased net cash provided by operating activities, reaching $14.3 billion for the nine-month period, an increase of 16.0% year-over-year. This robust operational cash flow supports the company's financial flexibility and ability to manage its debt obligations, which were reduced during the period. Investors can take comfort in the continued revenue growth and strong operating cash flow generation, though the goodwill impairment warrants attention regarding the long-term care business outlook.

    Nov 3, 2021
  16. 2021-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2021

    CVS Health Corporation reported solid revenue growth for the second quarter and first half of 2021, driven by increases across all its major segments, particularly Pharmacy Services and Retail/LTC. Total revenues rose 11.1% for the quarter and 7.3% year-to-date compared to the prior year. While overall revenues were strong, operating income saw a slight decline of 7.6% for the quarter and 2.9% year-to-date, primarily due to the normalization of healthcare utilization in the Health Care Benefits segment as the impact of the COVID-19 pandemic shifted from the prior year's lows. The company demonstrated resilience with strong performance in its Pharmacy Services segment, benefiting from improved purchasing economics and increased claims volume. The Retail/LTC segment also showed significant revenue growth, bolstered by prescription volume and COVID-19 related services like vaccinations and testing. Despite these positive operational trends, investors should note the decrease in operating income driven by the comparison to a pandemic-influenced prior year and the ongoing investments in growth and operational enhancements.

    Aug 4, 2021
  17. 2021-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2021

    CVS Health Corporation reported solid financial results for the first quarter ended March 31, 2021, demonstrating revenue growth across all segments and a notable increase in net income. Total revenues rose by 3.5% year-over-year, reaching $69.1 billion, driven by growth in Premiums and Services. Net income attributable to CVS Health increased by 10.8% to $2.22 billion, with diluted earnings per share rising to $1.68 from $1.53 in the prior year period. The company's integrated business model, spanning Health Care Benefits, Pharmacy Services, and Retail/LTC, continues to show resilience, with each segment contributing to the overall performance. The company's liquidity remains strong, evidenced by positive cash flows from operating activities, although slightly lower than the prior year due to strategic payment timing. Management highlighted the company's ability to navigate the ongoing impacts of COVID-19, with efforts focused on cost savings and operational efficiencies expected to continue benefiting the company. Despite ongoing litigation and regulatory risks, CVS Health expressed confidence in its ability to manage these, with no individual or aggregate material adverse effects anticipated from these matters at this time.

    May 4, 2021
  18. 2020-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2020

    CVS Health Corporation reported solid revenue growth for the nine months ended September 30, 2020, driven by increases across all segments. Total revenues rose by 4.9% year-over-year to $199.15 billion. The company saw a notable 10.6% increase in Premiums revenue in the third quarter, contributing to overall revenue growth. Operating income also showed significant improvement, increasing by 27.2% for the nine-month period to $11.39 billion, bolstered by the sale of the Workers' Compensation business and improved purchasing economics in the Pharmacy Services segment. Despite challenges related to COVID-19 impacting certain operational aspects and expenses, CVS Health demonstrated resilience and improved profitability. Net income attributable to CVS Health for the nine months ended September 30, 2020, increased by 27.0% to $6.21 billion, or $4.72 per diluted share. The company's balance sheet remained strong, with total assets increasing to $232.9 billion. The company's liquidity position was also healthy, with $9.26 billion in cash and cash equivalents. Key strategic moves during the period included the extinguishment of significant debt, demonstrating active capital management. The company continues to navigate the evolving healthcare landscape, with a focus on its integrated health services model.

    Nov 6, 2020
  19. 2020-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2020

    CVS Health Corporation reported a strong financial performance for the second quarter of 2020, with total revenues increasing by 3.0% to $65.34 billion compared to the same period in 2019. This growth was driven by increases across all segments, particularly in Premiums and Products. Despite incremental operating expenses related to COVID-19 response, the company saw a significant increase in operating income of 40.5% to $4.68 billion, largely due to a substantial decrease in benefit costs within the Health Care Benefits segment, a direct consequence of deferred elective procedures and reduced discretionary utilization during the pandemic. Net income attributable to CVS Health surged by 53.7% to $2.98 billion, or $2.26 per diluted share, reflecting the operational efficiencies and the favorable impact of the pandemic on certain cost structures. The company also demonstrated robust operational cash flow, increasing by 43.1% to $10.42 billion for the first six months of 2020, bolstered by tax payment deferrals and reduced benefit costs. The company maintained a strong liquidity position with $14.87 billion in cash and cash equivalents as of June 30, 2020.

    Aug 5, 2020
  20. 2020-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2020

    CVS Health Corporation reported solid revenue growth for the first quarter of 2020, with total revenues increasing by 8.3% year-over-year to $66.8 billion. This growth was driven by strong performance across all segments, notably the Pharmacy Services and Retail/LTC segments, which saw increased demand and early prescription refills due to the onset of the COVID-19 pandemic. Net income attributable to CVS Health surged by 41.2% to $2.0 billion, or $1.53 per diluted share. The company demonstrated strong operational cash flow, increasing by 69.7% to $3.3 billion, and bolstered its liquidity by issuing $4 billion in senior notes, ending the quarter with a robust cash position of $10.1 billion. The company provided significant insights into the initial impacts of the COVID-19 pandemic, noting increased demand in retail and pharmacy services, but also acknowledging potential future uncertainties and operational expense increases. Despite the challenging macroeconomic environment, CVS Health maintained its quarterly dividend and has substantial capacity under its existing share repurchase program, though no shares were repurchased in the quarter. Overall, the report indicates a strong financial performance driven by core business growth and, to some extent, the pandemic's immediate effects, while also highlighting proactive measures to manage liquidity and future uncertainties.

    May 6, 2020
  21. 2019-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2019

    CVS Health Corporation reported solid financial results for the nine months ended September 30, 2019, with total revenues increasing by 35.5% to $189.9 billion, largely driven by the transformative Aetna acquisition completed in late 2018. Net income attributable to CVS Health significantly improved, reaching $4.9 billion for the nine-month period, a substantial turnaround from a net loss in the prior year, primarily due to the absence of a large goodwill impairment charge and the positive contribution of Aetna. The company's operating segments showed varied performance. Pharmacy Services demonstrated steady growth in both revenue and adjusted operating income, driven by increased claims volume and improved purchasing economics. The Retail/LTC segment experienced revenue growth but faced margin pressures, while the Health Care Benefits segment, significantly expanded by the Aetna acquisition, showed dramatic revenue and operating income increases, underscoring the strategic importance of this integration. The company also highlighted its ongoing efforts to manage costs and pursue synergies from the Aetna acquisition, projecting approximately $800 million in synergies by 2020.

    Nov 6, 2019
  22. 2019-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2019

    CVS Health Corporation's (CVS) Q2 2019 filing reveals significant revenue growth, primarily driven by the integration of the Aetna acquisition which closed in late 2018. Total revenues for the quarter increased by 35.2% year-over-year, reaching $63.4 billion, with the Health Care Benefits segment showing the most dramatic expansion due to Aetna's inclusion. Despite this top-line growth, operating expenses also surged by 65.2%, largely attributable to acquisition-related costs, including intangible asset amortization. The company reported a net income of $1.94 billion for the quarter, a substantial turnaround from a net loss of $2.56 billion in the same period last year. This improvement is largely due to the absence of a significant goodwill impairment charge ($3.9 billion) that impacted the prior year's results. The Pharmacy Services and Retail/LTC segments demonstrated modest revenue growth, driven by increased prescription volumes, though both faced ongoing pressures from price compression and reimbursement challenges.

    Aug 7, 2019
  23. 2019-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2019

    CVS Health Corporation reported a significant increase in total revenues for the first quarter of 2019, reaching $61.6 billion, up 34.8% year-over-year. This growth was largely driven by the Aetna acquisition completed in November 2018, which significantly boosted the Health Care Benefits segment. Despite revenue growth, the company faced challenges in its traditional segments. Pharmacy Services and Retail/LTC segments experienced price compression and reimbursement pressures, leading to a decrease in adjusted operating income for Pharmacy Services and a more substantial decline for Retail/LTC. The company is actively managing these pressures through cost reduction efforts and new product initiatives, aiming to navigate this transition year and build towards long-term growth.

    May 1, 2019
  24. 2018-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2018

    CVS Health's Q3 2018 10-Q shows a company in transition ahead of its pending Aetna acquisition. Net revenues rose 2.4% to $47.3 billion for the quarter and 2.4% to $139.7 billion year to date, driven by pharmacy network and mail claim volume growth and brand inflation, partially offset by price compression and reimbursement pressure. Operating profit fell sharply year to date to $2.7 billion from $6.4 billion, primarily because of a $3.9 billion pre-tax goodwill impairment on the LTC (Omnicare) reporting unit taken in Q2 2018. Excluding that charge, operating performance was broadly stable, though the LTC unit's fair value exceeded its carrying value by only about 2% at quarter-end, so further impairment risk remains. Quarterly net income was $1.39 billion, up from $1.29 billion, and diluted EPS was $1.36 versus $1.26. The balance sheet changed materially. Long-term debt jumped to $60.7 billion from $22.2 billion after the March 2018 issuance of $40 billion of notes, which funds the proposed $69 billion equity-value (about $77 billion including assumed debt) Aetna acquisition. Cash rose to $41.6 billion, and the company received DOJ clearance on October 10, 2018, subject to divestiture of Aetna's standalone Part D plans, with closing expected in Q4 2018. Investors should weigh the leverage increase, the $2.1 billion termination fee exposure if the deal fails, and the mandatory 101% redemption requirement tied to the September 2019 outside date. Operating cash flow fell to $6.4 billion from $8.1 billion, mainly from timing of CMS payments, and share repurchases were suspended, with no buybacks in the period. The filing also discloses ongoing legal and regulatory exposure, including multiple qui tam and state Medicaid suits over the CVS Health Savings Pass program, opioid litigation, DEA audits, and insulin and PBM pricing investigations. Management states that none of the individual accruals are material, but the company cannot predict outcomes with certainty.

    Nov 6, 2018
  25. 2018-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2018

    CVS Health's Q2 2018 10-Q is dominated by a $3.9 billion pre-tax goodwill impairment on its Long-Term Care (LTC/Omnicare) reporting unit, which drove a GAAP net loss of $2.56 billion for the quarter (EPS of -$2.52) versus net income of $1.10 billion a year earlier. Excluding the charge, the underlying business showed growth: net revenues rose 2.2% to $46.7 billion, gross profit rose 4.0%, and Pharmacy Services mail choice and network claim volumes grew about 9.5% and 5.9%, respectively. Retail pharmacy same-store sales rose 8.3% in the quarter, though front-store sales were weak. Management attributed the impairment to LTC client retention problems, lower skilled nursing occupancy, customer financial stress, and reimbursement pressure, and the remaining LTC goodwill of about $2.7 billion is explicitly flagged as at risk of a further material impairment if forecasts are missed. The balance sheet changed dramatically because of the pending $69 billion (about $77 billion including debt) Aetna acquisition. CVS issued $40.0 billion of senior notes in March 2018, lifting cash to $43.8 billion and long-term debt to $61.6 billion, and total debt principal reached $65.9 billion. Shareholder equity fell to $35.6 billion from $37.7 billion, largely due to the loss. Operating cash flow was $5.3 billion for the six months, and share repurchases were suspended. If the Aetna deal fails to close by September 3, 2019, CVS must redeem most of the new notes at 101%, and a $2.1 billion termination fee could be owed to Aetna. The DOJ issued a second request for information in February 2018, so regulatory approval remains the central uncertainty. For investors, the key issues are the credibility of LTC's turnaround, the leverage added by the Aetna financing, the timing and conditions of DOJ clearance, and whether ongoing pricing pressure in PBM and retail reimbursement erodes the core margins that have been holding up.

    Aug 8, 2018
  26. 2018-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2018

    CVS Health's first-quarter 2018 10-Q shows revenue growth and stable core profitability, overshadowed by a large balance-sheet transformation tied to the pending Aetna acquisition. Net revenues rose 2.6% to $45.7 billion, gross profit rose 4.4% to $6.9 billion, and operating profit rose 8.5% to $1.95 billion. Diluted EPS from continuing operations was $0.98, up from $0.92 a year earlier, helped by a lower effective tax rate of 32.1% (versus 37.3%) following the Tax Cuts and Jobs Act. Interest expense, net rose $221 million, driven largely by $161 million of bridge facility fee amortization and interest on the newly issued debt. The most significant development is the $40.0 billion of senior notes issued on March 9, 2018, which lifted cash to $42.0 billion and long-term debt to $61.6 billion at quarter-end (total debt principal of $65.9 billion). Net proceeds are earmarked to fund the roughly $69 billion equity portion of the Aetna acquisition (about $77 billion including assumed debt). The DOJ issued a second request on February 1, 2018, and the merger remains subject to regulatory approvals. Investors should note that CVS would owe Aetna a $2.1 billion termination fee in certain failure scenarios, and that the notes must be redeemed at 101% if the deal is not completed by September 3, 2019. Operating cash flow fell to $2.4 billion from $3.5 billion, and the company did not repurchase shares under its 2016 program during the quarter, with $13.9 billion remaining authorized. Shareholders' equity was $38.7 billion. Management kept the company's long-term debt investment-grade (Baa1/BBB), but S&P's downgrade to BBB following the notes issuance reflects the added leverage. The LTC reporting unit's goodwill remains a watch item, with only a small fair-value cushion, and the company faces a large set of ongoing legal and government investigations, including multiple opioid-related matters.

    May 2, 2018
  27. 2017-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2017

    CVS Health's Q3 2017 10-Q shows a business under visible pressure at the top line and in margins, though profitability held up better than gross profit alone suggests. Net revenues rose 3.5% to $46.2 billion in the quarter and 3.7% to $136.4 billion year to date, driven by Pharmacy Services growth in claim volume, specialty pharmacy, and net new business. However, gross profit fell 4.9% in the quarter to $7.1 billion, and gross margin compressed about 135 basis points to 15.4%, reflecting PBM price compression, reimbursement pressure, and a mix shift toward the lower-margin Pharmacy Services segment. Retail/LTC revenue declined 2.7% in the quarter as marketplace network changes cost CVS Pharmacy prescription volume and front-store same-store sales fell 2.8%. Diluted EPS from continuing operations was $1.26 in the quarter versus $1.43 a year earlier, down about 12%. The decline was driven by a $187 million pre-tax pension settlement loss recorded in other expense, a higher effective tax rate, and lower operating profit, which fell 11.5% to $2.5 billion. Share count reduction from buybacks (approximately $4.4 billion repurchased year to date) and a 16% higher dividend per share partly offset the earnings decline. Operating cash flow was steady at $8.1 billion, but cash generation was used to fund $7.4 billion of financing outflows, including debt repayments and buybacks, and cash declined to $2.5 billion. Balance sheet items to monitor include $5.1 billion of debt reduction through the nine months, a $135 million goodwill impairment in the RxCrossroads unit (since agreed to be sold to McKesson for $735 million), $211 million of store closure charges as about 70 underperforming stores are shut, and an LTC reporting unit whose fair value exceeded carrying value by only about 1%, creating impairment risk if results deteriorate. The company also faces a substantial and growing set of legal matters, including several opioid suits, insulin pricing class actions, and multiple government investigations, though management describes none as individually material to financial position.

    Nov 6, 2017
  28. 2017-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2017

    CVS Health's second-quarter 2017 results show top-line growth driven by the Pharmacy Services segment, but profitability was pressured. Net revenues rose 4.5% to $45.7 billion in the quarter and 3.7% to $90.2 billion for the six months, led by a 10.3% increase in pharmacy network claims. Gross profit, however, fell 1.1% in the quarter and gross margin compressed about 85 basis points to 15.2%, reflecting the mix shift toward lower-margin PBM business and reimbursement pressure. Diluted EPS from continuing operations rose to $1.07 from $0.86 in the quarter, but this was flattered by a 4.4% lower share count after aggressive buybacks, while six-month operating profit declined 13.9% to $3.9 billion. The Retail/LTC segment is the main concern. Revenue fell 2.2% in the quarter and operating profit dropped 17.5% to $1.4 billion, as same-store pharmacy sales declined on marketplace network exclusions that cut prescription volume by roughly 460 basis points. The company also recorded a $135 million goodwill impairment on its RxCrossroads unit, which is being explored for strategic alternatives, and $205 million in store-closure charges tied to its plan to close about 70 underperforming stores in 2017. Management guided that prescription growth will remain pressured through the rest of 2017. Balance-sheet and cash-flow metrics are mixed. Operating cash flow improved to $5.5 billion from $4.1 billion, though management attributed much of the gain to timing of Medicare Part D payments. CVS repurchased $4.0 billion of stock in the first half, with $14.3 billion remaining under the 2016 authorization, and paid $1.0 billion in dividends. Shareholders' equity fell to $34.1 billion from $36.8 billion because buybacks outpaced earnings. Investors should weigh the EPS improvement against softer underlying operating performance and the continuing reliance on share repurchases.

    Aug 8, 2017
  29. 2017-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2017

    CVS Health's first quarter 2017 results show top-line growth driven by its Pharmacy Services segment, offset by softness in Retail/LTC and margin compression. Net revenues rose 3.0% to $44.5 billion, led by an 8.5% increase in Pharmacy Services to $31.2 billion on 10.5% pharmacy network claim growth. However, gross profit fell 2.4% to $6.6 billion and gross margin declined about 80 basis points to 14.8%, reflecting price compression in PBM operations and a mix shift toward the lower-margin Pharmacy Services segment. Retail/LTC revenue fell 3.8% to $19.3 billion, with same-store pharmacy sales down 4.7%, driven by network exclusions that removed CVS Pharmacy from certain plans and by generic price deflation. Operating profit declined 17.9% to $1.79 billion, weighed down by a $199 million charge for closing 60 underperforming stores under the enterprise streamlining initiative. Diluted EPS from continuing operations was $0.92, down from $1.04, though the share count fell about 6% to 1,035 million, helped by an aggressive buyback. The company repurchased roughly 36.1 million shares for $3.6 billion in the quarter, and dividends per share rose to $0.50 from $0.425. Operating cash flow improved to $3.5 billion from $2.4 billion, largely due to timing of Medicare Part D payments, while free cash flow was about $3.1 billion. Investors should weigh the strong cash generation and capital return against the deteriorating retail fundamentals and margin pressure. The filing also discloses a growing litigation docket, including multiple opioid-related suits in West Virginia, insulin pricing class actions, and a Texas Medicaid suit tied to the Health Savings Pass program. Management reiterated investment-grade ratings (Baa1/BBB+), and the company's balance sheet remains manageable, with cash of $2.2 billion and long-term debt of $25.6 billion.

    May 2, 2017
  30. 2016-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2016

    CVS Health Corporation reported strong top-line growth in the third quarter of 2016, with net revenues increasing by 15.5% year-over-year, driven by acquisitions and organic growth in its Pharmacy Services and Retail/LTC segments. The company demonstrated robust operating profit growth, up 20.8% year-over-year, reflecting effective expense management and synergies from recent acquisitions. While revenue and profit figures are positive, investors should note a slight decrease in gross profit margin, attributed to a changing business mix and ongoing price compression in the Pharmacy Services segment. The company also incurred significant expenses related to the early extinguishment of debt, impacting net income. Despite these factors, CVS Health continues to execute its strategy, evidenced by substantial share repurchases and a new $15 billion repurchase program authorization, signaling confidence in future performance and commitment to shareholder returns.

    Nov 8, 2016
  31. 2016-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2016

    CVS Health Corporation reported strong revenue growth in the second quarter and first half of 2016, driven by its recent acquisitions of Omnicare and Target's pharmacies and clinics. Net revenues increased by 17.6% and 18.3% for the three and six-month periods, respectively. While gross profit dollars saw a healthy increase, the gross profit margin declined year-over-year due to a shift in business mix and ongoing pricing and reimbursement pressures across both the Pharmacy Services and Retail/LTC segments. A significant event impacting profitability was a substantial loss of $542 million on the early extinguishment of debt during the quarter, primarily related to refinancing efforts. This loss, combined with a slight increase in interest expense due to recent debt issuances to fund acquisitions, impacted net income, which decreased year-over-year. Despite these impacts, the company continues to execute its share repurchase program, demonstrating a commitment to returning capital to shareholders.

    Aug 2, 2016
  32. 2016-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2016

    CVS Health Corporation reported solid top-line growth in the first quarter of 2016, with net revenues increasing by 18.9% year-over-year to $43.2 billion. This growth was primarily driven by the inclusion of Omnicare and Target pharmacies, as well as increased prescription volume in both the Pharmacy Services and Retail/LTC segments. Despite revenue growth, net income attributable to CVS Health decreased by 6.1% to $1.15 billion ($1.04 per diluted share) from $1.22 billion ($1.07 per diluted share) in the prior year's first quarter. The company's strategic acquisitions are contributing to revenue expansion, but they also led to higher interest expenses due to increased debt. While gross profit dollars increased, the gross profit margin saw a slight decline due to a shift in business mix towards the lower-margin Pharmacy Services segment and ongoing pricing pressures. CVS Health continues its robust share repurchase program, spending approximately $2.1 billion in the quarter, underscoring a commitment to returning capital to shareholders.

    May 3, 2016
  33. 2015-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2015

    CVS Health Corporation reported strong performance for the nine months ended September 30, 2015, with net revenues increasing by 9.6% to $112.1 billion. This growth was driven by robust performance in both the Pharmacy Services and Retail/LTC segments, with the latter significantly bolstered by the acquisition of Omnicare, Inc. for approximately $9.6 billion in August 2015. Net income attributable to CVS Health increased by 12.5% to $3.74 billion for the same period, demonstrating effective operational execution and strategic acquisitions. The company also announced a proposed acquisition of Target's pharmacy and clinic businesses for $1.887 billion, indicating continued aggressive growth strategies. The balance sheet reflects substantial increases in goodwill and intangible assets, largely due to the Omnicare acquisition, alongside a significant increase in long-term debt to finance these strategic moves. Operating cash flow remained strong, although investing activities showed a significant outflow due to the acquisition. The company also continued its share repurchase program, returning capital to shareholders. Despite increased debt and integration costs, the financial health of CVS Health appears solid, supported by its diversified business model and strategic acquisitions. Overall, CVS Health demonstrated significant growth and executed major strategic initiatives during this period, positioning itself for continued expansion in the integrated healthcare and pharmacy market. Investors should note the substantial debt taken on to fund acquisitions and the ongoing integration efforts as key factors to monitor.

    Oct 30, 2015
  34. 2015-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2015

    CVS Health Corporation (CVS) reported solid financial results for the quarter and six months ended June 30, 2015, showcasing continued revenue growth driven by both its Pharmacy Services and Retail Pharmacy segments. Net revenues increased across both periods, reflecting growth in specialty pharmacy, increased pharmacy network claims, and comparable store sales in the retail segment. The company also demonstrated a commitment to returning value to shareholders through significant share repurchases. Strategically, CVS Health is actively pursuing growth through acquisitions, with the significant proposed acquisitions of Omnicare and Target's pharmacy and clinic businesses poised to further expand its integrated healthcare offerings and market reach.

    Aug 4, 2015
  35. 2015-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2015

    CVS Health Corporation reported solid financial results for the first quarter of 2015, demonstrating continued growth across its key business segments. Net revenues increased by 11.1% year-over-year, driven by robust performance in both the Pharmacy Services and Retail Pharmacy segments. The Pharmacy Services segment benefited from growth in specialty pharmacy and an increase in pharmacy network claims, while the Retail Pharmacy segment saw improvements in pharmacy same-store sales. Profitability metrics showed positive trends, with operating profit increasing by 5.4%. The company also made significant strides in returning capital to shareholders, repurchasing $2.0 billion in common stock during the quarter, underscoring a commitment to enhancing shareholder value. While facing pressures from generic drug price compression and reimbursement rate challenges, CVS Health's diversified business model and strategic initiatives appear to be effectively navigating these headwinds.

    May 1, 2015
  36. 2014-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2014

    CVS Health Corporation reported solid revenue growth for the third quarter and first nine months of 2014, driven by increases in both its Pharmacy Services and Retail Pharmacy segments. Net revenues rose by 9.7% for the quarter and 8.9% year-to-date. While gross profit increased in dollar terms, the gross profit margin slightly decreased due to a shift in business mix towards the lower-margin Pharmacy Services segment. A significant event impacting profitability was a substantial loss of $521 million on the early extinguishment of debt, related to a $2.0 billion tender offer for senior notes. Despite this, the company continued to execute its share repurchase program, buying back approximately $2.8 billion in stock year-to-date. The company also completed the acquisition of Coram LLC for approximately $2.1 billion, which is expected to bolster its specialty infusion services. Looking ahead, CVS Health faces ongoing pressures from generic drug introductions and reimbursement rate changes, but benefits from favorable industry trends like an aging population and expanded insurance coverage under the Affordable Care Act. The company maintains a strong liquidity position and believes its operating cash flows will be sufficient to fund future initiatives.

    Nov 4, 2014
  37. 2014-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2014

    CVS Health Corporation (CVS) reported strong financial performance for the period ending June 29, 2014, with a notable increase in net revenues and operating profit across both its Pharmacy Services and Retail Pharmacy segments. The company demonstrated robust top-line growth, driven by organic expansion and strategic acquisitions, particularly the integration of Coram LLC. Net income saw a significant increase compared to the prior year, reflecting improved operational efficiencies and the company's diversified business model. Investors can look to continued revenue growth, driven by both prescription and front-store sales, and a growing generic dispensing rate as positive indicators. The company also actively returned capital to shareholders through share repurchases and dividend increases, underscoring a commitment to shareholder value. While the company experienced increased operating expenses, largely due to the Coram acquisition and incremental store operating costs, these were largely offset by revenue growth, leading to improved operating profit margins. The company's strong cash flow generation supports its investment in growth initiatives, strategic acquisitions, and shareholder returns. Despite ongoing legal proceedings and regulatory scrutiny common in the healthcare industry, management appears confident in its ability to navigate these challenges and maintain its financial stability. Overall, the filing indicates a healthy and growing enterprise with a strategic focus on expanding its integrated healthcare offerings.

    Aug 5, 2014
  38. 2014-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2014

    CVS Health Corporation (CVS) reported strong financial results for the first quarter ended March 31, 2014. Net revenues increased by 6.3% year-over-year, driven by growth in both the Pharmacy Services and Retail Pharmacy segments. The Pharmacy Services segment saw particular strength from its specialty pharmacy business, including the recent acquisition of Coram LLC, and also benefited from increased generic dispensing rates. The Retail Pharmacy segment experienced growth in pharmacy same-store sales and revenue from new stores, despite a slight decrease in front-store sales, which was attributed to factors like weather and the timing of the Easter holiday. Profitability also showed improvement, with operating profit increasing by 19.7%. Net income rose to $1.129 billion from $954 million in the prior year's quarter, leading to a diluted EPS of $0.95, up from $0.77. The company also actively managed its capital, repurchasing approximately $0.8 billion of its common stock during the quarter. Key strategic initiatives, such as the pending generic sourcing venture with Cardinal Health, were also highlighted, positioning CVS Health for continued market presence and operational efficiency.

    May 2, 2014
  39. 2013-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2013

    CVS Health Corporation (CVS) reported its third-quarter and year-to-date results for the period ending September 30, 2013. The company demonstrated strong top-line growth, with net revenues increasing by 5.8% to $31.97 billion for the quarter and 2.4% to $93.98 billion for the nine-month period. This growth was driven by both the Pharmacy Services and Retail Pharmacy segments, supported by volume increases, drug cost inflation in specialty pharmacy, and same-store sales growth in retail. Profitability also saw a significant improvement, with operating profit rising 19.1% to $2.16 billion in the quarter and 18.2% to $5.83 billion year-to-date. This was bolstered by increased gross profit margins, particularly from higher generic drug sales across both segments, and a gain from a legal settlement. Diluted earnings per share increased to $1.02 for the quarter, up from $0.79 in the prior year. The company also continued its commitment to returning capital to shareholders through share repurchases and dividends, repurchasing $1.5 billion in the quarter and maintaining a substantial remaining authorization for future buybacks.

    Nov 5, 2013
  40. 2013-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2013

    CVS Health Corporation (CVS) reported a solid financial performance for the second quarter and the first half of 2013. The company demonstrated revenue growth, driven by both its Pharmacy Services and Retail Pharmacy segments. Key to this growth was an increase in prescription volume and favorable drug cost inflation in specialty pharmacy, alongside gains from new store openings in the retail segment. Despite challenges from increasing generic drug sales, which typically lower revenue per prescription, CVS Health managed to improve its gross profit margins due to higher generic dispensing rates and cost-saving initiatives. Profitability also saw a significant boost, with net income and earnings per share increasing compared to the prior year. The company continued its share repurchase program, returning capital to shareholders while maintaining a strong liquidity position. Management appears confident in the company's ability to navigate industry challenges, including regulatory scrutiny and competitive pressures, and remains focused on strategic growth and cost management.

    Aug 6, 2013
  41. 2013-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2013

    CVS Health Corporation (CVS) reported mixed results for the first quarter ended March 31, 2013. While net revenues remained relatively flat year-over-year, decreasing by a slight 0.1% to $30.8 billion, the company demonstrated improved profitability. Net income attributable to CVS Caremark increased significantly by 23.3% to $956 million, leading to a substantial 30% rise in basic earnings per share from continuing operations to $0.78 and diluted EPS from continuing operations to $0.77. This earnings growth was driven by a robust increase in gross profit, up 9.1%, primarily due to a higher generic dispensing rate across both the Pharmacy Services and Retail Pharmacy segments, and improved gross margins in the Retail Pharmacy segment. Despite the positive earnings trend, operating expenses increased by 4.7% driven by higher store operating costs and legal expenses. The company also saw a decrease in net cash provided by operating activities, largely due to a timing difference in Medicare Part D payments. CVS Health continued its share repurchase program, buying back approximately $393 million of common stock. The company faces ongoing legal proceedings and investigations, though management believes these will not have a material adverse effect. Overall, the quarter shows operational improvements leading to enhanced profitability, but investors should note the increased operating expenses and cash flow dynamics.

    May 1, 2013
  42. 2012-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2012

    CVS Health Corporation (CVS) reported strong top-line growth for the nine months ended September 30, 2012, with net revenues increasing by 16.4% to $91.7 billion compared to the same period in 2011. This growth was driven by solid performance in both the Pharmacy Services and Retail Pharmacy segments, benefiting from new client wins, drug cost inflation, and increased prescription volumes. The company's profitability also saw a significant increase, with net income attributable to CVS Caremark rising by 14.6% to $2.75 billion. Operationally, CVS Health continued its aggressive share repurchase program, demonstrating a commitment to returning capital to shareholders. The company also maintained a strong cash flow from operations, indicating financial health and the ability to fund ongoing operations and strategic initiatives. Despite the positive financial results, the company faces ongoing legal matters and potential regulatory challenges inherent in the healthcare and PBM industries, which are disclosed but management believes will not have a material adverse effect.

    Nov 6, 2012
  43. 2012-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2012

    CVS Health Corporation (CVS) reported strong revenue growth for the second quarter and first half of 2012, with net revenues increasing by 16.3% and 18.0% respectively, compared to the prior year periods. This growth was driven by solid performance in both the Pharmacy Services and Retail Pharmacy segments, bolstered by new client wins, drug cost inflation, and strategic acquisitions. The company demonstrated improved operating profit, reflecting effective expense management and sales leverage. Diluted earnings per share also saw a notable increase, signaling enhanced profitability. Financially, CVS Health maintained a healthy liquidity position, with significant cash provided by operating activities. The company continued its share repurchase program, returning capital to shareholders. While gross profit margins experienced some pressure, particularly in the Pharmacy Services segment due to competitive pricing and client demands, overall financial results indicate a positive trajectory and robust operational execution.

    Aug 7, 2012
  44. 2012-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2012

    CVS Health Corporation (CVS) reported robust financial performance for the first quarter of 2012, with net revenues increasing by 19.9% to $30.8 billion compared to the same period in 2011. This growth was driven by strong contributions from both the Pharmacy Services and Retail Pharmacy segments. The company's net income attributable to CVS Caremark rose to $776 million, translating to earnings per diluted share of $0.59, an increase from $0.52 in the prior year quarter. The company also highlighted significant improvements in operating cash flow, which surged to $2.8 billion, up from $1.9 billion in the prior year period, reflecting efficient working capital management. Key drivers for the revenue growth included the acquisition of the UAM Medicare PDP Business and new PBM client starts within the Pharmacy Services segment, alongside strong same-store sales and new store openings in the Retail Pharmacy segment. The company also executed a substantial share repurchase program, buying back $810 million worth of stock in the quarter, demonstrating a commitment to returning value to shareholders. Despite some margin compression in the Pharmacy Services segment due to competitive pricing pressures and increased operating costs, overall financial health appears strong with positive trends across key operational and financial metrics.

    May 2, 2012
  45. 2011-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2011

    CVS Health Corporation (CVS) reported solid revenue growth in the third quarter and first nine months of 2011, driven by its Pharmacy Services and Retail Pharmacy segments. Net revenues increased by 12.5% and 10.7% for the respective periods, largely attributable to a new long-term contract in Pharmacy Services and consistent same-store sales in Retail Pharmacy, bolstered by the acquisition of the UAM Medicare Part D Business. Despite revenue growth, gross profit margins saw some pressure, particularly in the Pharmacy Services segment, due to pricing compression and increased sharing of rebates. The company also highlighted its continued focus on operational efficiency and strategic growth initiatives, including significant share repurchases and capital expenditures for store development. Financially, CVS maintained a strong liquidity position with substantial cash flow from operations. The company completed a significant debt issuance and continued to execute its share repurchase programs, signaling confidence in its financial health and commitment to returning value to shareholders. While facing ongoing industry challenges like reimbursement pressures and generic drug introductions, CVS demonstrated resilience by growing its store base and improving operational leverage. The company continues to navigate a complex regulatory and competitive landscape, with ongoing litigation and investigations noted but not deemed material to its financial condition.

    Nov 3, 2011
  46. 2011-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2011

    CVS Caremark Corporation reported solid revenue growth for the second quarter and first half of 2011, driven by a combination of a significant new contract win in its Pharmacy Services segment and continued strength in its Retail Pharmacy segment. Revenue increased by 10.9% for the quarter and 9.9% for the year-to-date period, reflecting the integration of the acquired UAM Medicare Part D Business and organic growth. While revenue saw a healthy increase, gross profit margins experienced some compression, particularly in the Pharmacy Services segment, due to contract renewals with lower pricing and increased sharing of manufacturer rebates. The company's operating expenses also saw an increase, largely attributed to integration costs from the UAM acquisition and efforts to streamline operations, though these were partially offset by disciplined expense controls and improved operating leverage in the retail segment. Despite margin pressures, the overall financial results indicate continued business expansion and strategic execution.

    Aug 4, 2011
  47. 2011-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2011

    CVS Health Corporation (CVS) reported its first-quarter 2011 results, showing solid revenue growth driven by both its Pharmacy Services and Retail Pharmacy segments. Net revenues increased by 8.9% year-over-year to $25.9 billion. While gross profit remained relatively flat in dollar terms, the gross profit margin saw a slight compression, primarily due to pricing pressures in the Pharmacy Services segment. Diluted earnings per share were $0.52, a decrease from $0.55 in the prior year period, reflecting these margin pressures. The company continues to execute its strategic initiatives, including expansion in the Retail Pharmacy segment with new store openings and growth in same-store sales. The Pharmacy Services segment benefited from a new contract with a large health insurance carrier and increased claim volumes. Despite the competitive landscape and ongoing legal and regulatory matters, CVS Health demonstrated a strong operating cash flow of $1.9 billion and actively managed its capital through share repurchases and debt management.

    May 5, 2011
  48. 2010-Q3

    CVS HEALTH Corp Quarterly Report for Q3 Ended Sep 30, 2010

    CVS Health Corp (CVS) reported its third-quarter 2010 results, showing a slight decrease in net revenues compared to the prior year. This was primarily driven by the termination of large client contracts and a decrease in Medicare Part D covered lives within the Pharmacy Services segment, partially offset by growth in the Retail Pharmacy segment from same-store sales and new store openings. Profitability saw a mixed performance. While gross profit dollars remained relatively stable, gross profit margins experienced slight pressure in the Pharmacy Services segment due to regulatory changes and competitive pricing, while the Retail Pharmacy segment saw a marginal improvement in gross profit margin. Operating expenses increased, largely due to higher store operating costs and litigation expenses. Diluted earnings per share for the quarter also saw a decline compared to the prior year. Investors should note the ongoing legal proceedings and regulatory investigations, particularly those related to government claims processing and controlled substances, which represent potential future risks.

    Nov 3, 2010
  49. 2010-Q2

    CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2010

    CVS Health Corporation (CVS) reported a slight decrease in net revenues for both the three and six-month periods ending June 30, 2010, compared to the prior year. This was primarily attributed to the termination of large client contracts and a decrease in covered lives under the Medicare Part D program within its Pharmacy Services segment. Despite the revenue dip, gross profit saw a minor decline, indicating some operational resilience. Operating expenses increased slightly, driven by higher litigation and store operating costs, while interest expense also saw a modest rise due to an increased debt balance. The company repurchased a significant amount of its stock during the period, completing its $2.0 billion repurchase program and initiating a new one, signaling a strong focus on returning capital to shareholders. Cash flow from operations improved year-over-year, driven by better working capital management.

    Jul 29, 2010
  50. 2010-Q1

    CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2010

    CVS Caremark Corporation reported a modest increase in net revenues for the first quarter of 2010, reaching $23.76 billion, up from $23.39 billion in the same period of 2009. This growth was driven by the Pharmacy Services segment, partly due to accounting changes in contract revenue recognition for RxAmerica, and by same-store sales and new store openings in the Retail Pharmacy segment. While gross profit remained relatively stable year-over-year, operating expenses saw a decrease, contributing to a rise in operating profit to $1.41 billion from $1.38 billion. Net income attributable to CVS Caremark increased to $771 million, translating to diluted earnings per share of $0.55, up from $0.50 in the prior year. The company also demonstrated a strong operating cash flow of $1.06 billion, a significant improvement from $771 million in Q1 2009. Despite facing headwinds from client contract terminations and competitive pressures in the PBM market, CVS Caremark continues to execute its growth strategy, including share repurchases and dividend increases, while navigating a complex regulatory and legal environment.

    May 4, 2010